QURENasdaqPharmaceutical PreparationsFiscal year ends December 31
uniQure N.V.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$22.20+0.42 (+1.93%)
Close on Oct 19, 2026
- Market cap
- $1.47B
- P/E (TTM)
- –
- Dividend yield
- –
uniQure N.V. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License revenues | – | – | $5.52M | $3.58M | $5.26M | $1.57M | $4.95M | $2.11M | $1.87M | $1.20M | $1.47M | $497.00K | – | – |
| Collaboration revenues | – | – | $45.00K | $119.00K | – | – | $270.00K | $176.00K | $7.13M | $3.29M | $982.00K | $561.00K | – | – |
| Contract manufacturing revenues | – | – | – | – | – | – | $0 | $0 | $2.12M | $3.99M | $4.24M | $349.00K | – | – |
By region
From the segment and revenue-disaggregation notes of uniQure's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.